Technology
Health
Medical
Check-Cap
$2.319876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.03 (1.32%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Check-Cap and other stocks, options, ETFs, and crypto commission-free!
About
Check-Cap Ltd. Ordinary Share, also called Check-Cap, is a clinical stage medical diagnostics company, which engages in developing gastrointestinal imaging devices. Read More It develops capsule-based system that utilizes low-dose X-rays to detect polyps, masses and colorectal cancer screening. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.
CEO
Employees
—
Headquarters
Mount Carmel, Haifa
Founded
2005
Market Cap
12.22M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
174.08K
High Today
$2.42
Low Today
$2.25
Open Price
$2.32
Volume
16.84K
52 Week High
$4.74
52 Week Low
$1.62
Collections
Technology
Health
Medical
Cancer Prevention
2015 IPO
Asia (Non-China)
Asia
News
Yahoo FinanceMay 13
Check-Cap Announces Second Trial Site Joins Ongoing U.S. Pilot Study of C-Scan®
Mayo Clinic joins New York University in pilot study of C-Scan® in the U.S. ISFIYA, Israel, May 13, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that Mayo Clinic is the second trial site participating in the Co...
Price Paid on Robinhood
42% Lower
Right Now
52 Week Low
$1.62
Average Price Paid
$4.00
52 Week High
$4.74
Earnings
-$1.68
-$1.16
-$0.64
-$0.12
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.46 per share
Actual
-$0.44 per share